|
AUPO755097A0
(en)
*
|
1997-06-25 |
1997-07-17 |
University Of Queensland, The |
Receptor agonist and antagonist
|
|
AUPQ339899A0
(en)
|
1999-10-13 |
1999-11-04 |
University Of Queensland, The |
Novel molecules
|
|
CA2418652C
(en)
|
2000-08-10 |
2010-03-23 |
Mitsubishi Pharma Corporation |
Novel 3-substituted urea derivatives and medicinal use thereof
|
|
WO2002022556A1
(en)
|
2000-09-14 |
2002-03-21 |
Mitsubishi Pharma Corporation |
Novel amide derivatives and medicinal use thereof ugs
|
|
AUPR833401A0
(en)
*
|
2001-10-17 |
2001-11-08 |
University Of Queensland, The |
G protein-coupled receptor antagonists
|
|
US8524862B2
(en)
|
2002-03-19 |
2013-09-03 |
Cincinnati Children's Hospital Medical Center |
Muteins of C5a anaphylatoxin and methods of inhibiting C5a
|
|
CA2480082A1
(en)
*
|
2002-03-29 |
2003-10-16 |
Neurogen Corporation |
Combination therapy for the treatment of conditions with pathogenic inflammatory components
|
|
AUPS160602A0
(en)
*
|
2002-04-08 |
2002-05-16 |
University Of Queensland, The |
Therapeutic method
|
|
AU2002950657A0
(en)
|
2002-08-08 |
2002-09-12 |
Alchemia Limited |
Derivatives of monosaccharides for drug discovery
|
|
AU2003266858B2
(en)
*
|
2002-10-11 |
2006-09-14 |
Vast Bioscience Pty Limited |
Classes of compounds that interact with GPCRs
|
|
AU2002951995A0
(en)
*
|
2002-10-11 |
2002-10-31 |
Alchemia Limited |
Classes of compounds that interact with gpcrs
|
|
JP4818726B2
(ja)
*
|
2002-10-16 |
2011-11-16 |
プロミクス・プロプライエタリー・リミテッド |
炎症性腸疾患の治療
|
|
AU2002952086A0
(en)
*
|
2002-10-16 |
2002-11-07 |
The University Of Queensland |
Treatment of osteoarthritis
|
|
AU2002952129A0
(en)
*
|
2002-10-17 |
2002-10-31 |
The University Of Queensland |
Treatment of hypersensitivity conditions
|
|
AU2003902354A0
(en)
*
|
2003-05-15 |
2003-05-29 |
Harkin, Denis W. |
Treatment of haemorrhagic shock
|
|
AU2003902586A0
(en)
*
|
2003-05-26 |
2003-06-12 |
The University Of Queensland |
Treatment of burns
|
|
WO2005014849A2
(en)
*
|
2003-07-03 |
2005-02-17 |
Euro-Celtique, S.A. |
Genes associated with responses to neuropathic pain
|
|
EP1498422A1
(de)
|
2003-07-17 |
2005-01-19 |
Jerini AG |
C5a-Rezeptor-Antagonisten
|
|
JP2008516194A
(ja)
*
|
2004-10-04 |
2008-05-15 |
アルケミア リミティッド |
選択的阻害剤
|
|
RU2007131267A
(ru)
*
|
2005-01-17 |
2009-02-27 |
Йерини Аг (De) |
АНТАГОНИСТЫ РЕЦЕПТОРА С5a
|
|
EP1861114B1
(en)
*
|
2005-03-11 |
2011-02-02 |
Potentia Pharmaceuticals, Inc. |
Compositions comprising modulators of g-protein-coupled receptor for treatment of macular degeneration
|
|
EP1739078A1
(de)
|
2005-05-30 |
2007-01-03 |
Jerini AG |
C5a-Rezeptor-Antagonisten
|
|
US20070292421A1
(en)
*
|
2005-07-28 |
2007-12-20 |
Feinberg Bruce B |
Method for treating preeclampsia
|
|
US8168584B2
(en)
|
2005-10-08 |
2012-05-01 |
Potentia Pharmaceuticals, Inc. |
Methods of treating age-related macular degeneration by compstatin and analogs thereof
|
|
HUE026001T2
(en)
|
2007-02-05 |
2016-04-28 |
Apellis Pharmaceuticals Inc |
Compstatin analogues for use in the treatment of the inflammatory condition of the respiratory system
|
|
WO2009015087A2
(en)
*
|
2007-07-20 |
2009-01-29 |
Potentia Pharmaceuticals, Inc. |
Compositions and methods for treatment of trauma
|
|
US20110190221A1
(en)
*
|
2008-03-28 |
2011-08-04 |
Apellis Ag |
Modulation and repletion/enhancement of the complement system for treatment of trauma
|
|
US20100000605A1
(en)
*
|
2008-07-02 |
2010-01-07 |
Saint-Gobain Performance Plastics Chaineux |
Framed device, seal, and method for manufacturing same
|
|
CA2742802C
(en)
|
2008-11-10 |
2019-11-26 |
Alexion Pharmaceuticals, Inc. |
Methods and compositions for treating complement-associated disorders
|
|
WO2011091366A2
(en)
*
|
2010-01-22 |
2011-07-28 |
University Of Louisville Research Foundation, Inc. |
Methods of treating or preventing periodontitis and diseases associated with periodontitis
|
|
MX340696B
(es)
|
2010-04-30 |
2016-07-21 |
Alexion Pharma Inc |
Anticuerpos anti-c5a y metodos para usar los anticuerpos.
|
|
WO2012006149A2
(en)
*
|
2010-06-29 |
2012-01-12 |
Board Of Regents Of The University Of Nebraska |
Analogs of c5a and methods of using same
|
|
EP2468295A1
(en)
*
|
2010-12-21 |
2012-06-27 |
Affiris AG |
Vaccines based on peptides of the complement protein C5a
|
|
EP3524258B1
(en)
|
2011-06-22 |
2025-10-01 |
Apellis Pharmaceuticals, Inc. |
Methods of treating chronic disorders with complement inhibitors
|
|
US9289467B2
(en)
|
2011-08-10 |
2016-03-22 |
Case Western Reserve University |
Compositions and methods for treating bone conditions
|
|
WO2014043223A1
(en)
*
|
2012-09-11 |
2014-03-20 |
Hospital For Special Surgery |
Irhom2 inhibition for the treatment of complement mediated disorders
|
|
MX366404B
(es)
|
2012-11-15 |
2019-07-08 |
Apellis Pharmaceuticals Inc |
Analogos de compstatina de celula reactiva, de acción prolongada u objetivos y composiciones y metodos relacionados.
|
|
WO2014152391A1
(en)
|
2013-03-15 |
2014-09-25 |
Apellis Pharmaceuticals, Inc. |
Cell-penetrating compstatin analogs and uses thereof
|
|
US10092620B2
(en)
*
|
2013-04-02 |
2018-10-09 |
The Scripps Research Institute |
Uses of cyclic peptides for treating and preventing atherosclerosis
|
|
SI3011345T1
(sl)
|
2013-08-07 |
2017-12-29 |
Alexion Pharmaceuticals, Inc. |
Biomarkerski proteini za atipični hemolitični uremični sindrom (ahus)
|
|
US11903994B2
(en)
|
2015-10-07 |
2024-02-20 |
Apellis Pharmaceuticals, Inc. |
Dosing regimens
|
|
US20190270778A1
(en)
|
2016-07-29 |
2019-09-05 |
Pfizer Inc. |
Cyclic Peptides As C5a Receptor Antagonists
|
|
US20200057046A1
(en)
|
2016-10-27 |
2020-02-20 |
Alexion Pharmaceuticals, Inc. |
Assay for c5b-9 deposition in complement-associated disorders
|
|
TWI826364B
(zh)
|
2017-04-03 |
2023-12-21 |
德商因夫萊亞斯有限公司 |
活性抑制劑於發炎性疾病之治療
|
|
IL269844B2
(en)
|
2017-04-07 |
2025-01-01 |
Apellis Pharmaceuticals Inc |
Dosage regimens and related compositions and methods
|
|
TWI786132B
(zh)
|
2017-06-23 |
2022-12-11 |
德商因夫萊亞斯有限公司 |
活性抑制劑於發炎性疾病之治療
|
|
WO2019118938A1
(en)
|
2017-12-15 |
2019-06-20 |
Apellis Pharmaceuticals, Inc. |
Dosing regimens and related compositions and methods
|
|
US20220356234A1
(en)
|
2019-10-02 |
2022-11-10 |
Alexion Pharmaceuticals, Inc. |
Complement inhibitors for treating drug-induced complement-mediated response
|
|
PH12022552556A1
(en)
|
2020-03-27 |
2024-04-22 |
Inflarx Gmbh |
Inhibitors of c5a for the treatment of corona virus infection
|
|
TW202208427A
(zh)
|
2020-05-06 |
2022-03-01 |
德商因夫萊亞斯有限公司 |
人源化抗ｃ５ａ抗體
|
|
JP2023525581A
(ja)
|
2020-05-15 |
2023-06-16 |
アレクシオン ファーマシューティカルズ， インコーポレイテッド |
補体の活性化を検出するための細胞外小胞の使用方法、並びに補体性疾患の処置を評価及び／又は監視するためのその使用
|
|
WO2024238422A1
(en)
|
2023-05-12 |
2024-11-21 |
Alexion Pharmaceuticals, Inc. |
Use of a panel of lectins for detection of complement biomarkers in urine extracellular vesicles
|
|
WO2024238421A1
(en)
|
2023-05-12 |
2024-11-21 |
Alexion Pharmaceuticals, Inc. |
Use of biomarkers for the identification and treatment of complement-mediated disorders
|
|
US12180274B2
(en)
|
2023-05-26 |
2024-12-31 |
Inflarx Gmbh |
Treatment of pneumonia and ARDS with inhibitors of C5a and IL-6 activity
|